Journal article
Fostamatinib for the treatment of warm antibody autoimmune hemolytic anemia: Phase 2, multicenter, open‐label study
Abstract
Patients with relapsed warm antibody autoimmune hemolytic anemia (wAIHA) have limited treatment options. Fostamatinib is a potent, orally administered spleen tyrosine kinase inhibitor approved in the United States and Europe for the treatment of adults with chronic immune thrombocytopenia (ITP). This phase 2 study evaluated the response to fostamatinib, administered at 150 mg BID orally with or without food in adults with wAIHA and active …
Authors
Kuter DJ; Rogers KA; Boxer MA; Choi M; Agajanian R; Arnold DM; Broome CM; Field JJ; Murakhovskaya I; Numerof R
Journal
American Journal of Hematology, Vol. 97, No. 6, pp. 691–699
Publisher
Wiley
Publication Date
June 2022
DOI
10.1002/ajh.26508
ISSN
0361-8609